Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis

Interstitial Cystitis Clinical Trial

Official title:

Therapeutic Efficacy and Safety of Low Energy Shock Wave (LESW) Plus Botulinum Toxin A Instillation in Treatment of Patients With Interstitial Cystitis Refractory to Conventional Therapy - A Clinical and Immunohistochemistry Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05275647
• Other study ID #: IRB 110-078-A
• Status: Recruiting
• Phase: Phase 2
• Start date: May 18, 2021
• Est. completion date: September 2024

Study information

• Verified date: March 2022
• Source: Buddhist Tzu Chi General Hospital
• Contact: Hann-Chorng Kuo, M.D.
• Phone: 886-3-8561825
• Email: hck[@]tzuchi.com.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low energy shock wave (LESW) is known to facilitate tissue regeneration with analgesic and anti-inflammatory effects. LESW treatment has been demonstrated effective in treatment of nonbacterial prostatitis and chronic pelvic pain syndrome. LESW reduced pain behavior and down-regulated the NGF expression, suppressed bladder overactivity by decreasing inflammation, IL-6 and COX2 expression and NGF expression. Previous rat interstitial cystitis (IC) models have shown LESW could increase urothelial permeability, facilitate intravesical botulinum toxin A (BoNT-A) delivery and block acetic acid induced hyperactive bladder, suggesting LESW might be a potential therapeutic candidate for relieving bladder inflammatory conditions and overactivity. A double-blind, randomized, placebo-controlled physician-initiated study revealed LESW treatment was associated with a statistically significant decrease in O'Leary-Saint Symptom Score and visual analog scale of pain in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), but the improvement was not superior to the sham LESW treatment. Previous studies found the urothelial dysfunction and deficits of cell differentiation are fundamental pathophysiology of IC/BPS. Through intravesical platelet-rich plasma injections, the chronic inflammation in IC/BPS bladders could be reduced and improved cell differentiation of urothelium. Botox injection or liposome encapsulated Botox could also inhibit inflammation and improve IC/BPS symptoms. However, the Botox injection needs anesthesia and certain complications might occur. There is no study to test if LESW plus Botox intravesical instillation could improve bladder inflammation and relieve IC/BPS symptoms. This study aims to investigate the therapeutic efficacy and safety of concomitant LESW plus intravesical BoNT-A instillation for IC/BPS refractory to conventional treatments.

Description:

Interstitial cystitis/ bladder pain syndrome (IC/BPS) is a bladder disorder with unknown etiology and difficult treatment. Novel treatments have been searched to adequately improved symptoms. Low energy shock wave (LESW) increased urothelial permeability, facilitated intravesical botulinum toxin A (BoNT-A) delivery and blocked acetic acid induced hyperactive bladder. Rats that received BoNT-A plus LESW showed a significantly reduced response (48.6% decreased intercontractile interval) to acetic acid instillation without compromising voiding function. Rats pre-treated with BoNT-A plus LESW showed a decreased inflammatory reaction (p <0.05), and decreased expressions of SNAP-23 (p < 0.05), SNAP-25 (p = 0.061) and COX-2 (p < 0.05) compared with the control group. These results support LESW as a promising method to deliver BoNT-A across urothelium without the need for injection. LESW is known to facilitate tissue regeneration with analgesic and anti-inflammatory effects. LESW treatment reduced pain behavior and down-regulated the NGF expression (33.3%, P < 0.05) on day 4 and IL-6 (40.9%, P < 0.05). LESW treatment suppressed bladder overactivity (intercontractile interval 77.8% increase, P < 0.05) by decreasing inflammation and COX2 (38.6%, P < 0.05) expression and NGF expression (25.2%, P = 0.0812). Previous study revealed that LESW might be a potential candidate for relieving bladder inflammatory conditions and overactivity. Recent clinical trial also revealed that Intravesical instillation of BoNT-A and LESW is a safe and effective method for the treatment of refractory overactive bladder with a durable response for 2 months. A double-blind, randomized, placebo-controlled physician-initiated study enrolled 54 patients with IC/BPS. The patients were assigned to LESW or placebo. At 4 weeks post-treatment, both groups were associated with a statistically significant decrease in OSS and VAS pain scale. A significantly higher proportion of patients on LESW responded as improved in the VAS ≥ 3 vs placebo (P = 0.035). At 12 weeks post-treatment, improvement in the VAS ≥ 3 was 57.1% vs 19.0% (LESW vs placebo; P = 0.011). No significant adverse events were found in either group. This study aims to investigate the therapeutic efficacy and safety of concomitant LESW plus intravesical BoNT-A instillation for IC/BPS patients refractory to conventional treatments.

Materials and Methods

Eligible participants of either gender with IC/BPS refractory to at least two treatments will be enrolled to this study. Participants are randomly allocated to receive either treatment in 1:1 ratio according to the permuted block randomization code as the following:

(A) LESW treatment with 3000 shocks, and followed by intravesical instillation of 30ml normal saline. (placebo group)

(B) LESW with 3000 shocks, and followed by intravesical BoNT-A 100U instillation. (treatment group)

Urine samples will be collected for urinary protein and biomarkers analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: September 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Adults with age of 20 years old or above

2. Patients with symptoms of frequency, urgency, and bladder pain at full bladder for more than 6 months.

3. Proven to have glomerulations (at least grade 1) by cystoscopic hydrodistention under anesthesia in recent 1 year

4. Free of active urinary tract infection

5. Free of bladder outlet obstruction on enrolment

6. Free of overt neurogenic bladder dysfunction and limitation of ambulation.

7. Patient or his/her legally acceptable representative agrees to sign the written informed consent form

Exclusion Criteria:

1. Patient's lower urinary tract symptoms can be effectively treated by conventional therapy

2. Patient or his/her legally acceptable representative cannot sign the written informed consent form

3. Patient cannot complete the consecutive 3- day voiding diary on the visiting day

4. Patient had been treated for overactive bladder by enterocystoplasty

5. Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up

6. Patient has bladder outlet obstruction on enrollment

7. Patients has post-void residual >250ml

8. Patients with uncontrolled confirmed diagnosis of acute urinary tract infection

9. Patients have laboratory abnormalities at screening including: ALT> 3 x upper limit of normal range, AST> 3 x upper limit of normal range; Patients have abnormal serum creatinine level > 2 x upper limit of normal range

10. Patient has coagulation disorder

11. Female patients who is pregnant, lactating, or with child-bearing potential without contraception.

12. Patients with any other serious disease considered by the investigator not in the condition to enter the trial

13. Patient had received intravesical hyaluronic acid insillation treatment for IC within recent 6 months before enrolment

14. Patient had received intravesical onabotulinumtoxinA treatment for IC within recent 12 months before enrolment

15. Patients participated investigational drug trial within 1 month before entering this study

Related Conditions & MeSH terms

• Cystitis
• Cystitis, Interstitial
• Interstitial Cystitis

Intervention

Drug:
• BOTOX 100U in normal saline
LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
• Normal saline
LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.

Locations

Country	Name	City	State
Taiwan	Buddhist Tzu Chi General Hospital	Hualien City

Sponsors (3)

Lead Sponsor	Collaborator
Buddhist Tzu Chi General Hospital	Hualien Tzu Chi General Hospital, Ministry of Science and Technology, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	O'Leary-Sant Symptom Score	Change of the O'Leary-Sant symptom score (including Interstitial Cystitis Symptom Index from 0 to 10 points and Interstitial Cystitis Problem Index, from 0 to 20 points; a higher score indicates a worse symptom severity)	from baseline to 3 month after the treatment day
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Local or systemic adverse events such as hematuria, miction pain, difficult urination, or any systemic symptoms such as fever, general weakness, dyspnea, etc.)	from baseline to 3 month after the treatment day
Secondary	Global response assessment (GRA)	Global response assessment (GRA) of satisfaction by the patient (categorized into -3, -2, -1, 0, 1, 2, 3 units of scale, indicating markedly worse to markedly improved) at 1 month after the treatment day.; An improvement of GRA by 2 units of scale at 1 month is considered effective.	1 month after the treatment day
Secondary	Visual analog score (VAS) for pain	Net change of the Visual analog score (VAS) for pain (from 0 to 10 units of scale, indicating no pain (0) to severe pain (10))	from baseline to 1 month and 3 months after the first treatment day
Secondary	Functional bladder capacity	Net change of functional bladder capacity (FBC, in milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Voiding frequency per day	Net change of voiding frequency at daytime and voiding frequency at night time as record in 3-day voiding diary	from baseline to 1 month and 3 months after the first treatment day
Secondary	maximum flow rate	Net changes of the maximum flow rate (Qmax, in milliliter/second)	from baseline to 1 month after the first treatment day
Secondary	voided volume	Net changes of the voided volume (in milliliter)	from baseline to 1 month after the first treatment day
Secondary	Pos-tvoid residual volume (PVR)	Net changes of the PVR (in milliliter)	from baseline to 1 month after the first treatment day
Secondary	urinary nerve growth factor (NGF)	Changes of urinary NGF level in urine (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	urinary brain derived neurotrophic factor (BDNF)	Changes of urinary BDNF (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Inflammatory cytokine IL-2 level	Changes of cytokine IL-2 level (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Inflammatory cytokines IL-6 level	Changes of cytokines IL-6 level (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Inflammatory cytokine IL-8 level	Changes of cytokine IL-8 level (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Inflammatory cytokine IL-1 beta level	Changes of cytokine IL-1 beta level (in nanogram/milliliter)	from baseline to 1 month and 3 months after the first treatment day
Secondary	Safety outcome (Local and systemic adverse events)	Any adverse events occurring after treatment, including hematuria, micturition pain, difficulty in urination, urinary tract infection, or systemic symptoms	from baseline to 1 month and 3 months after the first treatment day